MedyMatch Technology, a company based in Tel Aviv, Israel, leverages artificial intelligence, deep learning, and computer vision technologies to offer patient-specific clinical decision support. Their application helps radiologists and emergency room physicians to detect signs of intracranial hemorrhages, which are difficult to diagnose by standard analysis of imaging data alone. The Medgadget team recently had an opportunity to speak with Gene Saragnese, Chairman and Chief Executive Officer of MedyMatch, to discuss their technology and its significance in depth. Prior to joining MedyMatch in January of 2016, Gene was the Chief Executive Officer of Philips Imaging and a member of Philips Healthcare's Executive Team. A graduate of Rutgers College of Engineering in New Jersey, he has also previously served as GE Healthcare's Chief Technology Officer and has held management roles with GE, RCA, Martin Marietta, and Lockheed Martin.

MedyMatch Technology, a startup from Israel that specializes in medical imaging analysis for emergency medicine, has its first U.S. hospital partner. Capital Health, a two-hospital system in New Jersey, will deploy MedyMatch's artificial intelligence-based analytics in the emergency department and help the Tel Aviv-based vendor develop a clinical decision support tool for stroke care. To accomplish the latter, Capital Health, based in Hopewell Township, New Jersey, has agreed to provide MedyMatch with anonymized data from patients, the organizations said Monday. "The data Capital Health will provide will allow us to move closer to providing this decision support tool which can help ensure appropriate diagnosis, critical for treatment," MedyMatch Chairman and CEO Gene Saragnese said in a prepared statement. Saragnese was CEO of Philips Imaging before joining the startup a year ago.

Shepherds – yes, this is a reference to the popular medical drama "Grey's Anatomy" – who work in hospitals around the world may soon get a new assistant. No, not just another intern but an extra pair of virtual eyes to help them better diagnose stroke victims. Tel Aviv-based MedyMatch Technology Ltd., which hopes to have its first commercially available product as soon as the first half of 2017, is developing an artificial intelligence (AI) platform for critical areas of patient care. The platform is meant to help study data more quickly and accurately than the human eye, and help physicians with their clinical decisions in a wide set of healthcare issues. MedyMatch's first area of focus will be for stroke patients.